- Home
- PSTX vs CDXS Comparison
PSTX vs CDXS Comparison
Compare PSTX & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSTX
- CDXS
- Stock Information
- Founded
- PSTX 2014
- CDXS 2002
- Country
- PSTX United States
- CDXS United States
- Employees
- PSTX N/A
- CDXS N/A
- Industry
- PSTX Biotechnology: Biological Products (No Diagnostic Substances)
- CDXS Major Chemicals
- Sector
- PSTX Health Care
- CDXS Industrials
- Exchange
- PSTX Nasdaq
- CDXS Nasdaq
- Market Cap
- PSTX 360.4M
- CDXS 332.0M
- IPO Year
- PSTX 2020
- CDXS 2010
- Fundamental
- Price
- PSTX $2.71
- CDXS $4.33
- Analyst Decision
- PSTX Strong Buy
- CDXS Buy
- Analyst Count
- PSTX 2
- CDXS 2
- Target Price
- PSTX $15.00
- CDXS $11.00
- AVG Volume (30 Days)
- PSTX 557.2K
- CDXS 684.7K
- Earning Date
- PSTX 11-07-2024
- CDXS 10-31-2024
- Dividend Yield
- PSTX N/A
- CDXS N/A
- EPS Growth
- PSTX N/A
- CDXS N/A
- EPS
- PSTX N/A
- CDXS N/A
- Revenue
- PSTX $150,858,000.00
- CDXS $64,446,000.00
- Revenue This Year
- PSTX $64.38
- CDXS N/A
- Revenue Next Year
- PSTX N/A
- CDXS $2.02
- P/E Ratio
- PSTX N/A
- CDXS N/A
- Revenue Growth
- PSTX 203.18
- CDXS N/A
- 52 Week Low
- PSTX $1.87
- CDXS $1.85
- 52 Week High
- PSTX $4.27
- CDXS $4.91
- Technical
- Relative Strength Index (RSI)
- PSTX 46.81
- CDXS 69.15
- Support Level
- PSTX $2.63
- CDXS $3.70
- Resistance Level
- PSTX $2.82
- CDXS $4.20
- Average True Range (ATR)
- PSTX 0.33
- CDXS 0.29
- MACD
- PSTX -0.03
- CDXS 0.04
- Stochastic Oscillator
- PSTX 19.86
- CDXS 82.67
About PSTX Poseida Therapeutics Inc.
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.
About CDXS Codexis Inc.
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.